WCLC 2022 | MRD status in lung cancer

Federico Cappuzzo, MD, PhD, AUSL della Romagna-Ravenna, Ravenna, Italy, discusses the utility of minimal residual disease (MRD) status in lung cancer treatment. This approach can be used for various purposes, including screening, early detection and defining patients at risk for relapse following surgery and monitoring treatment response. Data on patients with early-stage disease, as well as data assessing MRD in patients with stage II or III lung cancer following surgery, will be presented at the IASLC 2022 World Conference on Lung Cancer congress (WCLC). This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.